Miriam Ana González-Cela-Casamayor

Miriam Ana González-Cela-Casamayor

Auto-generated profile, based on publicly available information

Miriam Ana González-Cela-Casamayor

Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal) Research Group (UCM 920415), Department of Pharmaceutics and Food Technology, Faculty of Pharmacy (UCM), Plaza Ramón y Cajal s/n, 28040 Madrid, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MGMiriam Ana González-Cela-Casamayor
Miriam Ana González-Cela-Casamayor
JLJosé López-Cano
José López-Cano
IBIrene Bravo-Osuna
Irene Bravo-Osuna
VAVanessa Andrés-Guerrero
Vanessa Andrés-Guerrero
MVMarta Vicario-de-la-Torre
Marta Vicario-de-la-Torre
IMIrene Teresa Molina-Martínez
Irene Teresa Molina-Martínez
Glaucoma is a group of chronic irreversible neuropathies that affect the retina and the optic nerve. It is considered one of the leading causes of blindness in the world. Although it can be due to various causes, the most important modifiable risk factor is the elevated intraocular pressure (IOP). In this case, the treatment of choice consists of instilling antihypertensive formulations on the ocular surface. The chronicity of the pathology, together with the low bioavailability of the drugs that are applied on the ocular surface, make it necessary to instill the formulations very frequently, which is associated, in many cases, with the appearance of dry eye disease (DED). The objective of this work is the design of topical ocular formulations capable of treating glaucoma and, at the same time, preventing DED. For this, two liposome formulations, loaded with brimonidine or with travoprost, were Tadeveloped using synthetic phospholipids and enriched by the addition of compounds with osmoprotective activity. The proposed formulations not only presented physicochemical characteristics (size, pH, osmolarity, surface tension, and viscosity) and encapsulation efficiency values (EE% of 24.78% and ≥99.01% for brimonidine and travoprost, respectively) suitable for ocular surface administration, but also showed good tolerance in human corneal and conjunctival cell cultures, as well as an in vitro osmoprotective activity. The hypotensive effect of both liposomal formulations was evaluated in normotensive albino New Zealand rabbits, showing a faster and longer lasting reduction of intraocular pressure in comparison to the corresponding commercialized products used as control. According to these results, the hypotensive liposomal formulations combined with osmoprotective agents would result in a very promising platform for the treatment of glaucoma and the simultaneous protection of the ocular surface.

24 April 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MVMarta Vicario-de-la-Torre
Marta Vicario-de-la-Torre
VPVirginia Puebla-García
Virginia Puebla-García
LYLidia Ybañez-García
Lidia Ybañez-García
JLJosé López-Cano
José López-Cano
MGMiriam Ana González-Cela-Casamayor
Miriam Ana González-Cela-Casamayor
RHRocio Herrero-Vanrell
Rocio Herrero-Vanrell
Compounded insulin eye drops were prepared at 1 IU/mL from commercially available subcutaneous insulin by dilution in saline solution or artificial tears. Physicochemical characterization and in vitro tolerance testing in human and conjunctival cells were followed by a 28-day short-term stability study under various conditions. The formulations were isotonic (280–300 mOsm/L), had a pH close to neutral (7–8), medium surface-tension values (<56 MN/m−1), and low (≈1 mPa·s) and medium (≈5 mPa·s) viscosities (compounded normal saline solution and artificial tear-based preparation, respectively). These values remained stable for 28 days under refrigeration. Microbiological stability was also excellent. Insulin potency remained in the 90–110% range in the compounded formulations containing normal saline solution when stored at 2–8 °C for 28 days, while it decreased in those based on artificial tears. Although both formulations were well tolerated in vitro, the compounded insulin diluted in a normal saline solution exhibited better cell tolerance. Preliminary data in humans showed that insulin in saline solution was an effective and safe treatment for persistent corneal epithelial defects. Compounded insulin eye drops diluted in normal saline solution could, therefore, constitute an emergent therapy for the treatment of persistent corneal epithelial defects.

Verified
Journal Article
Open access
PDF file
IMInes Munuera
Ines Munuera
AAAlba Aragon-Navas
Alba Aragon-Navas
PVPilar Villacampa
Pilar Villacampa
MGMiriam A. Gonzalez-Cela
Miriam A. Gonzalez-Cela
MSManuel Subías
Manuel Subías
MSMARIA JESUS RODRIGO SANJUAN
MARIA JESUS RODRIGO SANJUAN
To evaluate a new animal model of chronic glaucoma induced using a single injection of fibronectin-loaded biodegradable PLGA microspheres (Ms) to test prolonged therapies. 30 rats received a single injection of fibronectin-PLGA-Ms suspension (MsF) in the right eye, 10 received non-loaded PLGA-Ms suspension (Control), and 17 were non-injected (Healthy). Follow-up was performed (24 weeks), evaluating intraocular pressure (IOP), optical coherence tomography (OCT), histology and electroretinography. The right eyes underwent a progressive increase in IOP, but only induced cohorts reached hypertensive values. The three cohorts presented a progressive decrease in ganglion cell layer (GCL) thickness, corroborating physiological age-related loss of ganglion cells. Injected cohorts (MsF > Control) presented greater final GCL thickness. Histological exams explain this paradox: the MsF cohort showed lower ganglion cell counts but higher astrogliosis and immune response. A sequential trend of functional damage was recorded using scotopic electroretinography (MsF > Control > Healthy). It seems to be a function–structure correlation: in significant astrogliosis, early functional damage can be detected by electroretinography, and structural damage can be detected by histological exams but not by OCT. Males presented higher IOP and retinal and GCL thicknesses and lower electroretinography. A minimally invasive chronic glaucoma model was induced by a single injection of biodegradable Ms.